Blockbuster blood-thinner Pradaxa will come under scrutiny again, it appears. The FDA announced last Friday that it has established a study to evaluate post-trial safety outcomes in blood-thinning ...

The Food and Drug Administration (FDA) has grated accelerated approval to Praxbind (idarucizumab; Boehringer Ingelheim) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during ...

Pradaxa is under fire again. Should drug company executives who are responsible for turning a drug into a financial winner also have a say over how a drug's risks are communicated to doctors and ...

Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients 1–4 EU approval follows recent U.S. FDA approval ...

A review by the FDA finds no additional risk of myocardial infarcation (MI) or a heart attack when Pradaxa (dabigatran) is compared to Coumadin (warfarin). An MI occurs when blood suddenly stops ...

The FDA announced today that it was initiating a safety review of dabigatran (Pradaxa, Boehringer Ingelheim). The review was prompted by reports of serious bleeding events in people taking the drug.

Abstract sphere from a blood clot cells background. Scientific and medical microbiological concept. Enrichment with oxygen and important nutrients. Transfer of important elements, 3d illustration ...

The death of an elderly man from a massive brain hemorrhage after a routine fall suggests that bleeding complications from Boehringer Ingelheim's Pradaxa blood clot preventer are largely irreversible, ...

Boehringer Ingelheim is starting to inform physicians about a new contraindication for its oral anticoagulant drug Pradaxa (dabigatran). The company has told investigators in trials utilizing ...

The most effective journal ads of 2011 included those for Humira, Pradaxa and Conceptus’ Essure Procedure, according to the Doctors’ Choice Study. For the study, meant to show the value of print ...

Dallas, Nov 18 (Reuters) - An experimental antidote to the widely used blood clot preventer Pradaxa worked immediately and completely in an early-stage trial among healthy volunteers, raising hopes ...

The U.S. FDA has approved Kanuma as a first line of treatment for patients with a rare enzyme disease called LAL deficiency. Reuters/Jason Reed The U.S. Food and Drug Administration was “lax” and ...